March 5, 2019

Mutya Harsch
General Counsel and Chief Legal Officer
Foamix Pharmaceuticals Ltd.
2 Holzman Street, Weizmann Science Park
Rehovot 7670402
Israel

       Re: Foamix Pharmaceuticals Ltd.
           Preliminary Proxy Statement on Schedule 14A
           Filed March 1, 2019
           File No. 001-36621

Dear Ms. Harsch:

       We have reviewed your filing and have the following comment. In some of
our
comments, we may ask you to provide us with information so we may better
understand your
disclosure.

       Please respond to the comment within ten business days by providing the
requested
information or advise us as soon as possible when you will respond. If you do
not believe our
comment applies to your facts and circumstances, please tell us why in your
response.

       After reviewing your response to the comment, we may have additional
comments.

Preliminary Proxy Statement on Schedule 14A

Exhibits

1.    We note that for Proposals 3(a), 3(b), 6(a), 6(b) and 6(c), you have
indicated in the proxy
      card that if the shareholder does not mark any box with respect to being
a controlling
      shareholder or having a personal interest in the proposal, then it will
be deemed that such
      shareholder is not a controlling shareholder and has no personal
interest. However, these
      statements contradict your descriptions for these proposals and the boxed
disclosure at the
      top of page 9, where you state you may no longer assume that shareholders
have no
      personal interest and that if a shareholder does not confirm the lack of
personal interest,
      the holder's proxy will not be voted on these proposals. Please reconcile
your disclosures.
        We remind you that the company and its management are responsible for
the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action
or absence of
action by the staff.
 Mutya Harsch
Foamix Pharmaceuticals Ltd.
March 5, 2019
Page 2

       Please contact Dorrie Yale at 202-551-8776 or Mary Beth Breslin at
202-551-3625 with
any questions.



FirstName LastNameMutya Harsch                           Sincerely,
Comapany NameFoamix Pharmaceuticals Ltd.
                                                         Division of
Corporation Finance
March 5, 2019 Page 2                                     Office of Healthcare &
Insurance
FirstName LastName